MX2020011290A - Ligandos dirigidos a la integrina y sus usos. - Google Patents

Ligandos dirigidos a la integrina y sus usos.

Info

Publication number
MX2020011290A
MX2020011290A MX2020011290A MX2020011290A MX2020011290A MX 2020011290 A MX2020011290 A MX 2020011290A MX 2020011290 A MX2020011290 A MX 2020011290A MX 2020011290 A MX2020011290 A MX 2020011290A MX 2020011290 A MX2020011290 A MX 2020011290A
Authority
MX
Mexico
Prior art keywords
integrin
targeting ligands
compounds
cargo molecules
integrin targeting
Prior art date
Application number
MX2020011290A
Other languages
English (en)
Inventor
Zhen Li
Anthony Nicholas
Jeffrey Carlson
Matthew Fowler-Watters
Xiaokai Li
Dongxu Shu
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MX2020011290A publication Critical patent/MX2020011290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen compuestos que tienen afinidad con integrinas, la síntesis de esos compuestos y el uso de esos compuestos como ligandos para facilitar la administración de moléculas de carga a células que expresan integrinas. Los ligandos de direccionamiento a integrinas descritos tienen estabilidad en suero y afinidad con integrina avß3 y/o integrina avß5 y son adecuados para la conjugación con moléculas de carga, tales como agentes terapéuticos basados en oligonucléotidos (p. ej., agentes de RNAi), para facilitar la administración de las moléculas de carga a células y tejidos, tales como células tumorales, que expresan integrina avß3, integrina avß5 o ambas integrinas avß3 e integrina avß5. También se describen composiciones que incluyen ligandos de direccionamiento a integrinas y métodos de uso.
MX2020011290A 2018-04-27 2019-04-26 Ligandos dirigidos a la integrina y sus usos. MX2020011290A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862663763P 2018-04-27 2018-04-27
US201962790372P 2019-01-09 2019-01-09
PCT/US2019/029393 WO2019210200A1 (en) 2018-04-27 2019-04-26 Integrin targeting ligands and uses thereof

Publications (1)

Publication Number Publication Date
MX2020011290A true MX2020011290A (es) 2020-11-13

Family

ID=68294255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011290A MX2020011290A (es) 2018-04-27 2019-04-26 Ligandos dirigidos a la integrina y sus usos.

Country Status (17)

Country Link
US (1) US20210093725A1 (es)
EP (2) EP4435000A2 (es)
JP (1) JP2021522269A (es)
KR (1) KR20210005145A (es)
CN (1) CN112074290B (es)
AU (1) AU2019260738A1 (es)
BR (1) BR112020021949A2 (es)
CA (1) CA3097656A1 (es)
DK (1) DK3784269T3 (es)
FI (1) FI3784269T3 (es)
IL (2) IL278304B2 (es)
JO (1) JOP20200266A1 (es)
MX (1) MX2020011290A (es)
SG (1) SG11202009734VA (es)
SI (1) SI3784269T1 (es)
TW (1) TW202014206A (es)
WO (1) WO2019210200A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4367246A2 (en) * 2021-07-07 2024-05-15 Alnylam Pharmaceuticals, Inc. Integrin targeting ligands for ocular delivery of rnai compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
TR200002557T2 (tr) * 1997-12-17 2000-12-21 Merck & Co., Inc. İntegrin reseptörü antagonistleri
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
EP2268317B1 (en) * 2008-03-14 2020-02-26 VisEn Medical, Inc. Integrin targeting agents and in vivo and in vitro imaging methods using the same
RU2623441C2 (ru) * 2012-01-27 2017-06-26 Ф.Хоффманн-Ля Рош Аг Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим альфа-v-бета-3
SG11201506805QA (en) 2013-02-28 2015-09-29 Arrowhead Res Corp Organic compositions to treat epas1-related diseases
CA2919088A1 (en) 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugates for delivery of rnai triggers to tumor cells in vivo
CN114805342A (zh) * 2015-02-19 2022-07-29 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
WO2016172710A2 (en) * 2015-04-24 2016-10-27 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
EP3288555A1 (en) * 2015-04-30 2018-03-07 SciFluor Life Sciences, Inc. Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
TWI761305B (zh) 2015-05-29 2022-04-21 美商愛羅海德製藥公司 抑制Ｈｉｆ２α基因表現之組合物及方法

Also Published As

Publication number Publication date
SG11202009734VA (en) 2020-11-27
DK3784269T3 (da) 2024-07-08
AU2019260738A1 (en) 2020-10-15
EP3784269A1 (en) 2021-03-03
IL309955A (en) 2024-03-01
EP4435000A2 (en) 2024-09-25
SI3784269T1 (sl) 2024-08-30
EP3784269A4 (en) 2022-03-23
KR20210005145A (ko) 2021-01-13
CA3097656A1 (en) 2019-10-31
WO2019210200A1 (en) 2019-10-31
JP2021522269A (ja) 2021-08-30
BR112020021949A2 (pt) 2021-01-26
TW202014206A (zh) 2020-04-16
IL278304B1 (en) 2024-02-01
US20210093725A1 (en) 2021-04-01
CN112074290B (zh) 2024-09-10
FI3784269T3 (fi) 2024-07-03
IL278304B2 (en) 2024-06-01
EP3784269B1 (en) 2024-06-05
CN112074290A (zh) 2020-12-11
JOP20200266A1 (ar) 2020-10-21
IL278304A (es) 2020-12-31

Similar Documents

Publication Publication Date Title
PH12020550258A1 (en) Trispecific proteins and methods of use
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
Kanojia et al. Neural stem cells secreting anti-HER2 antibody improve survival in a preclinical model of HER2 overexpressing breast cancer brain metastases
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
Zhao et al. Biomimetic nanovesicles made from iPS cell-derived mesenchymal stem cells for targeted therapy of triple-negative breast cancer
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
MX2020009512A (es) Terapia de combinacion con agonistas de 4-ibb (cd137) direccionados.
EA201590207A1 (ru) Композиции и способы регуляции car-т-клеток
WO2013170272A3 (en) Site-specific labeling and targeted delivery of proteins for the treatment of cancer
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
WO2012112690A3 (en) Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
PH12015500186A1 (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
BR112012013664A2 (pt) rabdovírus oncolítico
SA520420109B1 (ar) أجسام مضادة
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
MX2018015914A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
MX2018007983A (es) Composiciones que se dirigen al dominio extracelular soluble de e-caderina y metodos relacionados para terapia de cancer.
PH12020550035A1 (en) Universal abt compounds and uses thereof
MX2021008261A (es) Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso.
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
Fernández-Tabanera et al. CD44 in sarcomas: a comprehensive review and future perspectives
Ikeda-Imafuku et al. Extracellular matrix degrading enzyme with stroma-targeting peptides enhance the penetration of liposomes into tumors
NZ750948A (en) Anti-gp73 antibodies and immunoconjugates
MX2020011290A (es) Ligandos dirigidos a la integrina y sus usos.